MOMM Diagnostics
MOMM Diagnostics is dedicated to bridging the gap in prenatal care by delivering reliable and accessible solutions. Through meticulous research and development, we strive to bring forth a game-changing technology that will revolutionize the way preeclampsia is detected and managed. We are driven by a shared purpose to improve maternal and fetal health outcomes, bringing peace of mind to families worldwide.

Our Purpose
Empowering healthcare professionals with accurate and timely diagnostic tools to improve the health and well-being of mothers and babies worldwide.
Our mission is to address the critical need for a timely, accurate, and affordable diagnostic tool for the early detection of preelampsia, a life-threatening condition affecting pregnant women and their unborn babies
Our vision is to create a future where life-threatening pregnancy conditions are effectively and proactively managed, reducing maternal and neonatal mortality rates. Through continuous innovation and collaboration, we aspire to establish our technology as the gold standard for near-patient testing, enabling early detection, personalized care, and positive outcomes for every expectant mother.
Our
Story
Founded in 2018, our startup emerged from a partnership between Avails Medical, Inc. and the Swiss research institute Empa. Since our inception, we have worked tirelessly to develop our groundbreaking eFlow technology and préXclude our pioneering rapid preeclampsia test. Our long history of collaborating with industry experts and renowned research institutions such as FHNW School of Life Sciences, CSEM, and Swiss TPH provide a unique ecosystem to make innovation happen.
Our Team
%20C_edited_edited.jpg)
CEO & Co-founder
Mathias Wipf, PhD
Mathias is an expert in electrical biosensors and in-vitro diagnostics. After his MSc in nanoscience and PhD in physics at the University of Basel, he worked on electrical immunoassay readout as a postdoc at Yale, developed bacterial infection diagnostics at Avails Medical in Silicon Valley, and led a biosensor team at Empa before co-founding MOMM in 2018. As CEO, he has built MOMM’s network of academic, clinical and industrial partners and secured substantial non-dilutive and equity funding. He has sharpened his entrepreneurial skills through programs such as Innosuisse Startup Coaching, Venturelab, Venture Kick and Venture Leaders MedTech.
%20C_edited_edited.jpg)
Director R&D
Christopher Wood, PhD
Chris is a chemist and bioengineer specialising in ultrasensitive point-of-care diagnostics, from assay development to antibody modification and nanomaterial synthesis. He studied chemistry at Oxford, earned his PhD at Cambridge, and gained IVD experience as a postdoc at Imperial College London and the Karolinska Institute before joining MOMM in 2020.

Project Manager préXclude®
Celine Gutmann
Celine combines over ten years as a healthcare professional with an MSc in Biomedical Engineering from FHNW and the University of Basel. Her first-hand understanding of clinical workflows shapes her work on MOMM’s plasma separation device and the préXclude® cartridge system.

Senior Scientist
Yosita Lackerbauer, PhD
Yosita leads product development of préXclude®, from immunoassay development and validation to transfer to manufacturing. She brings over ten years of IVD experience across lateral flow and microfluidic platforms, gained at Elionova AG and as a postdoc at Colorado State University, where she co-invented a point-of-care tuberculosis test. She holds a PhD in Biotechnology from Chulalongkorn University.

Biomedical Engineer
Sara Bieri
Sara works on hardware and software integration of MOMM’s eFlow-based test system. A trained nurse, she spent five years in hospital care at Inselspital Bern, giving her first-hand insight into how diagnostics are used at the point of care. She holds an MSc in Biomedical Engineering from FHNW and the University of Basel.
Board of Directors
Oren Knopfmacher, PhD
Oren is a nanotechnology and biochemical sensor expert and CEO and co-founder of Avails Medical, a Silicon Valley company developing rapid antibiotic susceptibility tests. He earned his PhD in experimental physics at the University of Basel, working on silicon nanowire FET biosensors, followed by a postdoc at Stanford University and the Stanford GSB Ignite Program.
Meike Herget, PhD
Meike is co-founder and CTO of Avails Medical. She holds a PhD in Biochemistry from Goethe University Frankfurt and did her postdoctoral research at Stanford Medical School on membrane proteins in synaptic transmission. Driven to turn science into products, she has since co-founded two diagnostics companies, Avails Medical and MOMM, and brings hands-on experience in building technology ventures from the lab to the clinic.
Michael D. Laufer, MD
Mike is a physician, venture capitalist and serial medtech entrepreneur who has conceived and patented the technology behind more than 20 companies, including VNUS (acquired by Covidien), Asthmatx (acquired by Boston Scientific) and SurX. He brings deep experience in taking medical products from early development through FDA clearance to commercial growth, holds over 200 issued or pending patents, and teaches at Stanford Biodesign.
Anzhey Zhimbiew
Anzhey is CEO of LifeDX and an experienced executive in medical device development, business development and innovation management. He has a track record in bringing disruptive healthcare technologies to market, building high-performing teams, and combines this with a strong background in marketing and finance. As an investor in medical technologies, he led MOMM’s pre-seed round through Business Angels Switzerland and supports the company on strategy, governance and fundraising.
Advisors
Paul Sheard
Paul brings 40 years of experience in the in-vitro diagnostics sector. He has directed initiatives in biomarker validation, product development, and market access across women’s health and cardiometabolic health. He is widely recognised within the industry and by global key opinion leaders for his leadership in the successful introduction of the Alere Triage Placental Growth Factor (PlGF) test into clinical practice.
Matthew Cooper, PhD
Matt is a diagnostics entrepreneur with deep expertise in preeclampsia. He founded and led Carmenta Bioscience, a Stanford spin-out developing a protein-based preeclampsia test, and after its acquisition by Progenity joined the company as Chief Scientific Officer. He has served on the board of directors of the Preeclampsia Foundation and today is CEO of Enumera Molecular, a diagnostic platform company developing single-molecule detection for rapid, lower-cost liquid biopsy tests.
KAPSLY
KAPSLY (Kay Brunner & Vincent Irrling)
KAPSLY supports MOMM on strategy and fundraising. Dr. Kay Brunner brings senior leadership experience from the diagnostics and medtech industry, including roles as Senior Vice President at Roche Diagnostics and Commercial Director EMEA at Abbott Diabetes Care. He is joined by Managing Director Vincent Irrling (MBA, HSG).






